Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

This study has been withdrawn prior to enrollment.
Information provided by:
Genentech, Inc. Identifier:
First received: May 21, 2007
Last updated: May 11, 2017
Last verified: May 2017
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Enrollment: 0
Actual Study Start Date: June 2007
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed Informed Consent Form
  • Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

  • Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • Congenital long QT syndrome
  • Family history of long QT syndrome
  • Clinically significant bradycardia (defined as < 50 beats/minute)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00477425

Sponsors and Collaborators
Genentech, Inc.
Study Director: Jane Huang, M.D. Genentech, Inc.
  More Information Identifier: NCT00477425     History of Changes
Other Study ID Numbers: AVF4223g
Study First Received: May 21, 2007
Last Updated: May 11, 2017

Keywords provided by Genentech, Inc.:

Additional relevant MeSH terms:
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on May 25, 2017